Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ju, Zhang, Zhongyuan, Wu, Xinhua, Zhou, Jie, Meng, Deqian, Zhu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591221/
https://www.ncbi.nlm.nih.gov/pubmed/34790122
http://dx.doi.org/10.3389/fphar.2021.746396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591221/
https://www.ncbi.nlm.nih.gov/pubmed/34790122
http://dx.doi.org/10.3389/fphar.2021.746396

Ejemplares similares